Originally published in January 2021, this white paper offers essential background to the ongoing controversy over contract pharmacies in the 340B Drug Pricing Program. The conflict began in mid-2020 when a handful of drug manufacturers began denying 340B pricing on dispenses made at contract pharmacies, pointing to duplicate discounts and other compliance concerns.
Since then, there have been a number of new developments, including a new presidential administration and an ongoing legal battle. As of July 2021, the contract pharmacy conflict has not been resolved, with the continued strife causing stakeholder uncertainty, threatening 340B sustainability and ultimately putting patients at risk.
It’s a complicated issue, but it doesn’t have to be. Download Mitigate Risk, Embrace Opportunity to learn how tech-based solutions can resolve these conflicts, ensure contract pharmacy compliance and enable all stakeholders to collaborate for a successful 340B program and the good of patients.